



US008394406B2

(12) **United States Patent**
Chang et al.

(10) **Patent No.:** **US 8,394,406 B2**
(45) **Date of Patent:** ***Mar. 12, 2013**

(54) **ONCE DAILY FORMULATIONS OF TETRACYCLINES**

(75) Inventors: **Rong-Kun Chang**, Rockville, MD (US);
Arash Raoufinia, Springfield, VA (US);
Niraj Shah, Owings Mills, MD (US)

(73) Assignee: **Supernus Pharmaceuticals, Inc.**,
Rockville, MD (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **12/926,934**

(22) Filed: **Dec. 17, 2010**

(65) **Prior Publication Data**

US 2011/0288056 A1 Nov. 24, 2011

Related U.S. Application Data

(63) Continuation of application No. 12/155,676, filed on Jun. 6, 2008, which is a continuation of application No. 10/819,620, filed on Apr. 7, 2004, now Pat. No. 7,749,532.

(60) Provisional application No. 60/460,963, filed on Apr. 7, 2003, provisional application No. 60/547,964, filed on Feb. 26, 2004.

(51) **Int. Cl.**
A61K 9/54 (2006.01)

(52) **U.S. Cl.** **424/458**

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,293,539 A	10/1981	Ludwig et al.
4,666,897 A	5/1987	Golub et al.
4,704,383 A	11/1987	McNamara et al.
4,837,030 A	6/1989	Valorose, Jr. et al.
4,935,411 A	6/1990	McNamara et al.
4,935,412 A	6/1990	McNamara et al.
5,045,538 A	9/1991	Schneider et al.
5,122,519 A	6/1992	Ritter
5,167,964 A	12/1992	Muhammad et al.
5,188,836 A	2/1993	Muhammad et al.
5,223,248 A	6/1993	McNamara et al.
5,238,686 A	8/1993	Eichel et al.
5,258,371 A	11/1993	Golub et al.
5,260,292 A	11/1993	Robinson et al.
5,277,916 A	1/1994	Dwyer et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP	0 410 099 A1	1/1991
EP	0 464 932 B2	1/1992

(Continued)

OTHER PUBLICATIONS

Bayomi et al., "Preparation and Dissolution Characteristics of Prolonged Release Mebeverine-HCL Beads," Drug Development and Industrial Pharmacy, 1994, 20(17):2763-2773.


(Continued)

Primary Examiner — Paul Dickinson
(74) *Attorney, Agent, or Firm* — Foley & Lardner LLP; Stephen B. Maebius; Sunit Talapatra

(57) **ABSTRACT**

Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.

21 Claims, 6 Drawing Sheets



Dissolution profile for doxycycline monohydrate IR beads